ROMOSOZUMAB
Information current as at: 1 August 2025
PBAC meeting date: July 2022
Submission Details
- Brand name:
-
- Evenity®
- Pharmaceutical company:
- Amgen Australia Pty Limited
- Condition/indication:
(therapeutic use) -
- Osteoporosis
- PBAC Submission type:
- Change to PBS listing (Standard re-entry)
- Comment:
- --
- Public Summary Document:
- PBAC Public Summary Documents – July 2022
- Related medicines:
Progress Details
-
Submission received for: - July 2022 PBAC meeting
-
Opportunity for consumer comment: - Open 30/03/2022 and close 25/05/2022 (see PBS Website)
-
PBAC meeting: - Held on 06/07/2022
-
PBAC outcome published: - Not Recommended (see PBAC Outcomes)
-
Lodgement of required documentation: - 22/10/2022
-
Acceptance of complete documentation:
- Accepted
-
Agreement to listing arrangements: - Commenced on 09/11/2022
-
Status:
- Finalised
-
Government processes: - Commenced on 09/11/2022
-
Medicine listed on the PBS: - 01/02/2023 (see PBS schedule)
Case ID: a555
Page last updated: 30 June 2025